ClinicalTrials.gg
RecruitingNCT07579949Updated Nov 19, 2026

A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)

A Phase 2 interventional study of SNH-119014 dose 1 and SNH-119014 dose 2 in Thalassemia, sponsored by ScinnoHub Pharmaceutical Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by ScinnoHub Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.

Planned enrollment
14th of 27
30 · median 30
Started
2026
with 2 others
Phase 2
9 of 32
4 open now
Primary completion
2027-09
later than 9 of 13 live
Registered
31st of 32
by date

Among the 32 studies in Thalassemia with a site in China, this one is the 14th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 31st registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Thalassemia with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of treatment with SNH-119014 in adult participants with non-transfusion-dependent thalassemia. 30 participants with non-transfusion-dependent thalassemia were enrolled.

03

Conditions studied

  • Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female;

    -≥18 years;

  • Documented diagnosis of thalassemia;
  • Non-transfusion-dependent;
  • concentration ≤10.0 grams per deciliter (g/dL) during the screening period;
  • For women of : negative serum pregnancy test during the screening period;
  • Agreement to use approved measures;
  • ;

Exclusion criteria

Exclusion Criteria:

  • S forms of thalassemia;
  • History of Congestive Heart Failure Within 6 months prior to signed ;
  • Myocardial Infarction/unstable angina Within 6 months prior to signed informed consent;
  • Deep Vein Thrombosis/stroke/thromboembolic events Within 6 months prior to signed informed consent;
  • Poorly controlled hypertension or diabetes;
  • Markedly abnormal interval;
  • Severe arrhythmia requiring treatment as assessed by the investigator;
  • Markedly abnormal ;
  • Diagnosis of any other congenital or acquired hematologic disorder, or any other hemolytic process;
  • Active infection requiring intravenous antibiotics or of Grade ≥3 severity within 4 weeks prior to the first dose;
  • History of primary , except for: cured non-melanoma skin cancer; curatively treated cervical or breast carcinoma in situ; or other primary tumors treated with curative intent with no known active disease and no treatment in the past 5 years;
  • History of neurological or psychiatric disorders that, in the investigator's assessment, may affect the participant's ability to participate in the clinical study;
  • Post-splenectomy sepsis;
  • Severe pulmonary disease or hepatobiliary disease;
  • Abnormal laboratory tests during screening;
  • Use of luspatercept, hydroxyurea, erythropoietin, strong inhibitors, or strong CYP3A4 inducers within the prohibited period specified in the protocol;
  • Receipt of anticoagulant therapy prior to screening, or requirement for anticoagulant therapy during the study period;
  • Prior bone marrow or stem cell transplant;
  • Pregnant or lactating women;
  • Major surgery within 6 months prior to signing informed consent or planned during the study period;
  • Splenectomy scheduled during the study treatment period;
  • Participation in another clinical trial and receipt of treatment within 3 months;
  • History of severe allergy, or allergy to SNH-119014 or its ;
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for enrollment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Study Drug

    Drug: SNH-119014 dose 1

  • Experimental
    Cohort 2

    Study Drug

    Drug: SNH-119014 dose 2

  • Placebo comparator
    Cohort 3

    Placebo

    Drug: Placebo

Interventions

  • DrugSNH-119014 dose 1

    Study Drug

  • DrugSNH-119014 dose 2

    Study Drug

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety evaluation

    The incidence of Abnormal Laboratory Values, Clinically Significant Physical Examination Findings, vital signs, electrocardiogram (ECG) and/or Adverse Events

    Time frame: From signing the informed consent to 4 weeks after the last dose

07

Study locations

1 of 8 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 26 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's planned 15 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Mar 2027 → Sep 2027 and completion Apr 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 12, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Sep 30, 2027was Mar 2027
CompletionEst.
Dec 30, 2027was Apr 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
8 sites changed recruiting status (7 now not yet recruiting, 1 now recruiting)
Show 8 sites
  • Foshan First People's Hospital · Foshan, Chinano status→Not yet recruiting
  • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
  • Maoming People's Hospital · Maoming, Chinano status→Not yet recruiting
  • Liuzhou People's Hospital · Liuzhou, Chinano status→Not yet recruiting
  • 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China · Nanning, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Guangxi Medical University · Nanning, Chinano status→Recruiting
  • The First Affiliated Hospital of Hainan Medical University · Haikou, Chinano status→Not yet recruiting
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · Chengdu, Chinano status→Not yet recruiting
Nov 19, 2026
Start date
Jun 18, 2026→Jun 16, 2026 (actual)
Nov 19, 2026
Primary completion
Mar 29, 2027→Sep 30, 2027
Nov 19, 2026
Study completion
Apr 29, 2027→Dec 30, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    8 sites changed recruiting status (7 now not yet recruiting, 1 now recruiting)
    Show 8 sites
    • Foshan First People's Hospital · Foshan, Chinano status→Not yet recruiting
    • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
    • Maoming People's Hospital · Maoming, Chinano status→Not yet recruiting
    • Liuzhou People's Hospital · Liuzhou, Chinano status→Not yet recruiting
    • 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China · Nanning, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Guangxi Medical University · Nanning, Chinano status→Recruiting
    • The First Affiliated Hospital of Hainan Medical University · Haikou, Chinano status→Not yet recruiting
    • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · Chengdu, Chinano status→Not yet recruiting
    Start date Jun 18, 2026→Jun 16, 2026 (now actual)
    Primary completion Mar 29, 2027→Sep 30, 2027
    Study completion Apr 29, 2027→Dec 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07579949
Lead sponsor
ScinnoHub Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Jun 16, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Yongrong Lai, Ph.D
Contact
laiyongrong@263.net
0771-6356510

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion